stoxline Quote Chart Rank Option Currency Glossary
  
(AGMB)
  0 (0%)    05-25 00:34
Open:
High:
Volume: 0
  
Pre. Close:
Low:
Market Cap: 0(M)
Technical analysis
2024-05-24 4:53:04 PM
Short term     
Mid term     
Targets 6-month :  10.21 1-year :  11.04
Resists First :  8.74 Second :  9.46
Pivot price 8.54
Supports First :  7.59 Second :  6.32
MAs MA(5) :  8.01 MA(20) :  8.63
MA(100) :  8.95 MA(250) :  10.68
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  17.2 D(3) :  20.7
RSI RSI(14): 36.4
52-week High :  14.82 Low :  7.59
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GAMB ] has closed above bottom band by 25.2%. Bollinger Bands are 157.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.04 - 8.09 8.09 - 8.14
Low: 7.71 - 7.76 7.76 - 7.82
Close: 7.87 - 7.96 7.96 - 8.04
Company Description

Headline News

Fri, 15 Dec 2023
Agomab Therapeutics doses first subject in Phase I IPF drug trial - Clinical Trials Arena

Sat, 18 Nov 2023
AG Mortgage Bank Adopts Innovative Home Ownership Drive – THISDAYLIVE - THISDAY Newspapers

Wed, 11 Oct 2023
Agomab adds $100M in series C funds to push ALK5 inhibitor through phase 2 Crohn's trial - Fierce Biotech

Wed, 11 Oct 2023
Agomab Therapeutics NV raises US$100m in Series C financing - European Biotechnology News

Wed, 11 Oct 2023
Belgian biotech company Agomab Therapeutics raises €94.9M to tackle fibrosis; here's how - Silicon Canals

Fri, 06 Oct 2023
Agomab's FSCD therapy receives fast track designation - Pharmaceutical Technology

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
Sector:
Industry:
Shares Out 37 (M)
Shares Float 17 (M)
Held by Insiders 46 (%)
Held by Institutions 42.4 (%)
Shares Short 352 (K)
Shares Short P.Month 267 (K)
Stock Financials
EPS 0.46
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.19
Profit Margin 16.8 %
Operating Margin 27.2 %
Return on Assets (ttm) 12.6 %
Return on Equity (ttm) 17.7 %
Qtrly Rev. Growth 52.4 %
Gross Profit (p.s.) 0
Sales Per Share 2.91
EBITDA (p.s.) 0.81
Qtrly Earnings Growth 0 %
Operating Cash Flow 18 (M)
Levered Free Cash Flow 6 (M)
Stock Valuations
PE Ratio 16.93
PEG Ratio 0
Price to Book value 2.49
Price to Sales 2.72
Price to Cash Flow 16.54
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android